Crown Laboratories secures aesthetic division with Bellus Medical acquisition

December 8, 2018

Crown Laboratories has acquired Bellus Medical, allowing the firm to secure a variety of noninvasive aesthetic products, according to a company news release.

Crown Laboratories has acquired Bellus Medical, allowing the firm to secure a variety of noninvasive aesthetic products, according to a company news release.

The Dallas-based Bellus Medical is being renamed Bellus Aesthetics and represents the new Aesthetics Division of Crown Laboratories. The company produces microneedling protocol Skinfuse; ProGenTM/RegenLab, which are platelet-rich plasma systems; light-activated cream Allumera; and SkinPen, a microneedling device for the treatment of acne scars. SkinPen was the first microneedling device in the U.S. to be granted clearance by the Food and Drug Administration (FDA) for the facial acne scarring treatment indication, according to the company.

“Bellus has assembled a truly impressive team with an enviable track record of innovation in aesthetics,” Jeff Bedard, president and CEO of Crown Laboratories, said in a statement. “We believe there is tremendous opportunity for us in aesthetics, and with Bellus as the cornerstone of our new division, we expect to expand our portfolio meaningfully in the years ahead.”

Joe Proctor, CEO of Bellus, becomes president of Crown’s Aesthetics Division. He will also join the Crown Board of Directors, according to the news release.

download issueDownload Issue : Dermatology Times, December 2018 (Vol. 39, No. 12)